Ranibizumab (LUCENTIS®)

Phase 3

AbbVie Inc. (ABBV)

00%

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

11mo

ABBV⭐Phase 3$300.2B

Ranibizumab (LUCENTIS®) Phase 3 Results Expected

Ranibizumab (LUCENTIS®)• AMD630

Dec 15

CT.gov

00%

Drug Information

Target Indication

AMD

Clinical Trial

NCT04704921

Last updated: 1/13/2026

Regulatory Approvals

EMA1/22/2007

Lucentis

Lucentis is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to choroidal neovascularisation (CNV) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)

View on EMA

Developer

ABBV

AbbVie Inc.

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

EtentamigPhase 3

Multiple Myeloma

etanerceptPhase 3

Moderate to Severe Plaque Psoriasis

AzacitidinePhase 3

Acute Myeloid Leukemia (AML)

Bimatoprost (SR)Phase 3

Open-Angle Glaucoma

AcalabrutinibPhase 3

Chronic Lymphocytic Leukemia

View full pipeline